Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end

Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that patient screening in its DSC127 Phase 2 trial in diabetic foot ulcer healing will be completed tomorrow, and that enrollment in the trial will conclude on September 30. This randomized, double-blind, placebo controlled study of up to 75 patients will look at the percentage of diabetic ulcers completely healed over a 12-week period, among other outcomes. Top-line efficacy results are expected to be made public in late December 2010 or early January 2011.

Derma Sciences Chairman and Chief Executive Officer Edward J. Quilty said, "Should the DSC127 trial generate positive outcomes, we believe we will be able to attract several potential partners to handle further clinical testing of this drug and ultimately bring another treatment option to market for the millions of diabetics with chronic, non-healing foot ulcers. Given the 2.4 million diabetic foot ulcers and more than 60,000 diabetes-related amputations each year in the United States, the commercial potential of this drug is significant."

SOURCE Derma Sciences, Inc.